Determination of dolutegravir's unbound fraction in human plasma using validated equilibrium dialysis and LC-MS/MS methods.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinica chimica acta; international journal of clinical chemistry

• Publication date

  2018-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.cca.2017.12.034PMID 29277535
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?

  2017cited by this paper
• Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe.

  2017cited by this paper
• Development and Validation of a Chromatographic Ultraviolet Method for the Simultaneous Quantification of Dolutegravir and Rilpivirine in Human Plasma

  2016cited by this paper
• A Validated Method for Quantification of Dolutegravir Using Ultra Performance Liquid Chromatography Coupled With UV Detection

  2016cited by this paper
• HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.

  2016cited by this paper
• Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice

  2016cited by this paper
• The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.

  2016influential reference
• Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia.

  2016cited by this paper
• Challenges regarding analysis of unbound fraction of highly bound protein antiretroviral drugs in several biological matrices: lack of harmonisation and guidelines.

  2015cited by this paper
• Pharmacokinetics of Dolutegravir in a Premature Neonate after HIV Treatment Intensification during Pregnancy

  2015cited by this paper
• Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients

  2015influential reference
• A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma.

  2014influential reference
• Reference range of hemolysis index in serum and lithium-heparin plasma measured with two analytical platforms in a population of unselected outpatients.

  2014cited by this paper
• ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1–Infected, Antiretroviral Therapy–Naive Subjects

  2014influential reference
• Dolutegravir: A Review of Its Use in the Management of HIV-1 Infection in Adolescents and Adults

  2014cited by this paper
• A liquid chromatography-tandem mass spectrometry assay for quantification of rilpivirine and dolutegravir in human plasma.

  2014influential reference
• R: A language and environment for statistical computing.

  2014cited by this paper
• Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans

  2013cited by this paper
• Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir

  2013cited by this paper
• A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.

  2013cited by this paper
• Effects of Fatty Acids and Glycation on Drug Interactions with Human Serum Albumin.

  2013cited by this paper
• The bioanalytical challenge of determining unbound concentration and protein binding for drugs.

  2013influential reference
• Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls

  2013influential reference
• Characterization of Binding of Raltegravir to Plasma Proteins

  2013cited by this paper
• Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment

  2013influential reference
• Determination of unbound fraction of imatinib and N-desmethyl imatinib, validation of an UPLC-MS/MS assay and ultrafiltration method.

  2012cited by this paper
• Therapeutic Drug Monitoring

  2012cited by this paper
• Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

  2011cited by this paper
• Red blood cell (RBC) membrane proteomics--Part I: Proteomics and RBC physiology.

  2010cited by this paper
• A prospective study of causes of haemolysis during venepuncture: tourniquet time should be kept to a minimum

  2009cited by this paper
• Pharmacokinetic-Pharmacodynamic Modeling and Simulation.

  2007cited by this paper
• High-throughput determination of the free fraction of drugs strongly bound to plasma proteins.

  2004cited by this paper
• The impact of hemolysis on Ortho-Clinical Diagnostic's ECi and Roche's elecsys immunoassay systems.

  2004cited by this paper
• Lopinavir Protein Binding In Vivo Through the 12-Hour Dosing Interval

  2004cited by this paper
• The effect of blood drawing techniques and equipment on the hemolysis of ED laboratory blood samples.

  2003cited by this paper
• Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS.

  2003cited by this paper
• Shift in pH of biological fluids during storage and processing: effect on bioanalysis.

  2003cited by this paper
• Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectrometry: important factors for method optimization.

  2002cited by this paper
• Red blood cell hemolysis during processing.

  2002cited by this paper
• Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins.

  2000cited by this paper
• Therapeutic drug monitoring

  1999cited by this paper
• Clinical pharmacokinetics : concepts and applications

  1989cited by this paper
• Haemolysis as an interference factor in clinical chemistry.

  1986cited by this paper
• Plasma concentrations of unbound phenytoin in the management of epilepsy.

  1984cited by this paper
• Decreased drug binding in uraemia: effect of indoxyl sulphate and other endogenous substances on the binding of drugs and dyes to human albumin.

  1982cited by this paper

• Establishment and application of a rapid method for the determination of both total and unbound anlotinib concentrations by high-performance liquid chromatography-tandem mass spectrometry.

  2025cites this paper
• A developed and validated centrifugal ultrafiltration coupled with high performance liquid chromatography-tandem mass spectrometry method for rapid quantification of unbound lenvatinib in human plasma.

  2024cites this paper
• Dolutegravir quantification in wistar rat tissues following chronic administration

  2023cites this paper
• Development and validation of equilibrium dialysis UHPLC-MS/MS measurement procedures for total and unbound concentrations of bictegravir, dolutegravir, darunavir and doravirine in human plasma. Application to patients with HIV.

  2023cites this paper
• Comprehensive Review on Different Analytical Techniques for HIV 1- Integrase Inhibitors: Raltegravir, Dolutegravir, Elvitegravir and Bictegravir

  2022cites this paper
• Determination of free and total meropenem levels in human plasma and its application for the consistency evaluation of generic drugs.

  2022cites this paper
• Analisis Senyawa Dolutegravir dalam Berbagai Sampel Biologis

  2022cites this paper
• Pharmacokinetics and placental transfer of dolutegravir in pregnancy.

  2021cites this paper
• Development of a simple and rapid method to determine the unbound fraction of dolutegravir, raltegravir and darunavir in human plasma using ultrafiltration and LC-MS/MS.

  2021cites this paper
• Maraviroc exposure is influenced by exogenous thyrotoxicosis.

  2021cites this paper
• First report for the electrochemical investigation of a new HIV integrase inhibitor dolutegravir: Its voltammetric determination in tablet dosage forms and human urine using a boron-doped diamond electrode

  2021cites this paper
• Comparing ultrafiltration and equilibrium dialysis to measure unbound plasma dolutegravir concentrations based on a design of experiment approach

  2020cites this paper
• Three Heterocyclic Rings Fused (6-6-6)

  2020cites this paper
• HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy.

  2019cites this paper
• Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically‐Based Pharmacokinetic Modeling

  2019cites this paper
• Dolutegravir Plasma Protein Binding and Unbound Concentrations During Pregnancy and Postpartum

  year unknowncites this paper